RxDoctor Payments Data

Paul Liva, MD

Ophthalmology · Hackensack, NJNPI 1245293877

Payments from drug & device makers

$3,816in general payments, 2019–2025

Across 153 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bausch & Lomb Americas Inc.$656
  • Oyster Point Pharma, Inc.$494
  • Sun Pharmaceutical Industries Inc.$307
  • Aerie Pharmaceuticals, Inc.$231
  • Johnson & Johnson Surgical Vision, Inc.$125
  • plus $434 from 11 others

What the payments were for

  • Food & beverage$3,816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,816 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$152,359
Medicare patients
661
Services billed
1,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$89,871
LumiganBimatoprost87$47,507
XiidraLifitegrast20$34,615
CombiganBrimonidine Tartrate/Timolol68$30,149
MieboPerfluorohexyloctane/Pf29$29,723
Alphagan PBrimonidine Tartrate41$26,430
Dorzolamide-TimololDorzolamide/Timolol/Pf33$7,318
Cyclosporine11$6,669
RocklatanNetarsudil Mesylat/Latanoprost12$5,950
Tobramycin-DexamethasoneTobramycin/Dexamethasone150$5,687
Latanoprost385$4,449
Brinzolamide17$3,798
Brimonidine Tartrate56$3,714
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat260$3,554
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$1,570$193,957252 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$656$64,33849 claims
Aerie Pharmaceuticals, Inc.Rocklatan$231$5,95012 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$27$2,36519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →